منابع مشابه
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
BACKGROUND The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS Eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day 1, whereas bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) for patients o...
متن کاملIntravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
OBJECTIVES To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). MATERIALS AND METHODS Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus exami...
متن کاملHearing improvement after bevacizumab in patients with neurofibromatosis type 2.
BACKGROUND Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors. METHODS We determined the expression pattern of vascular endothelial growth factor (VEGF) and three of its receptors, VEGFR-2, neuropi...
متن کاملBevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
BACKGROUND Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas, meningiomas, and spinal ependymomas. There have been anecdotal reports of radiographic response of spinal ependymomas in NF2 patients being treated for progressive vestibular schwannomas with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF). AIMS...
متن کاملتزریق داخل زجاجیه‌ای Bevacizumab در مبتلایان به گلوکوم نورگ‌زایی
هدف: تعیین اثر تزریق داخل زجاجیه‌ای Bevacizumab (IVB) در بیماران مبتلا به گلوکوم نورگ‌زایی (NVG). روش پژوهش: مطالعه به روش کارآزمایی بالینی تصادفی‌شده بر روی 26 چشم از 26 بیمار مبتلا به NVG انجام شد. بیماران پس از انجام درمان‌های رایج به دو گروه تقسیم شدند: گروه درمان (14 چشم) که تحت IVB به میزان 5/2 میلی‌گرم در سه نوبت به فاصله زمانی 4 هفته قرار گرفتند و گروه شاهد (12 چشم) که با فواصل زمان...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2010
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.99.1605